Hosted on MSN1mon
Supernus stock price target raised to $44 at TD Cowen
The inclusion of Onapgo in Supernus' offerings has prompted the analysts at TD Cowen to revise their discounted cash flow (DCF)-derived price target upwards.
Hosted on MSN1mon
Supernus stock climbs 5% on FDA approval of Onapgo
Shares of Supernus Pharmaceuticals (NASDAQ:SUPN) rose 5% Tuesday morning on news the FDA has approved its wearable treatment device Onapgo, formerly known as SPN-830, for the treatment of patients ...
Yahoo Finance1mon
Supernus wins FDA approval for Parkinson’s pump on fourth try
Supernus Pharmaceuticals has won US approval for its wearable pump Onapgo (apomorphine hydrochloride) to treat symptoms of Parkinson’s disease. Supernus’ regulatory path for Onapgo has been ...
ADVFN1mon
Supernus Announces FDA Approval of ONAPGO™ (apomorphine hydrochloride) for Parkinson’s Disease
Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, announced ...
The Globe and Mail1mon
Supernus Announces Fourth Quarter and Full Year 2024 Financial Results
ONAPGO™ (apomorphine hydrochloride), formerly known as SPN-830, approved by the U.S. Food and Drug Administration and will be launched in the second quarter of 2025. Full year 2025 guidance for ...
Business Insider1mon
Supernus reports Q4 EPS 27c, consensus 52c
Reports Q4 revenue $174.2M, consensus $155.25M. “Our 2024 results reflect solid commercial execution across the company, including continued growth of our core products, and strong growth in ...
Investing1mon
Supernus Pharmaceuticals Q4 revenue beats, EPS misses estimates
ROCKVILLE, Md. - Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) reported fourth quarter 2024 financial results that exceeded revenue expectations but fell short on earnings per share. The company's ...
clinicaladvisor.com1mon
Apomorphine Infusion Device Onapgo Approved for Parkinson Disease
Patients should receive training on the proper use of the delivery device prior to starting treatment. The Food and Drug Administration (FDA) has approved Onapgo™ (apomorphine hydrochloride [HCl ...
manilatimes1mon
Supernus Announces Fourth Quarter and Full Year 2024 Financial Results
ONAPGO™ (apomorphine hydrochloride), formerly known as SPN-830, approved by the U.S. Food and Drug Administration and will be launched in the second quarter of 2025. Full year 2025 guidance for total ...
Investing1mon
Supernus Pharmaceuticals Q4 revenue beats, EPS misses estimates
ROCKVILLE, Md. - Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) reported fourth quarter 2024 financial results that exceeded revenue expectations but fell short on earnings per share. The company’s ...
Business Insider1mon
Supernus Announces Fourth Quarter and Full Year 2024 Financial Results
Fourth quarter 2024 net sales of Qelbree ® increased 60% to $74.4 million, compared to the same period in 2023. Full year 2024 net sales of Qelbree increased 72% to $241.3 million, compared to ...